Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.

The global Oncolytic Virus Cancer Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.

This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Cancer Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Cancer Immunotherapy.

Report Scope

The Oncolytic Virus Cancer Immunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncolytic Virus Cancer Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oncolytic Virus Cancer Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Oncolytic Virus Cancer Immunotherapy Market Report

Report Metric	Details
Report Name	Oncolytic Virus Cancer Immunotherapy Market
Segment by Type	Monoclonal Antibodies Checkpoint Inhibitors Oncoloytic Viral Therapies and Cancer Vaccines
Segment by Application	Lung Cancer Breast Cancer Colorectal Cancer Melanoma Prostate Cancer Head and neck Cancer Ovarian Cancer Pancreatic Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Amgen, F Hoffman-La Roche, Bristol-Myers Squibb, Novartis AG, Merck & Co., Inc., Pfizer, Biovex, Cell Genesys, Crusade Laboratories, Genelux Corporation, Lokon Pharma, MultiVir
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncolytic Virus Cancer Immunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Oncolytic Virus Cancer Immunotherapy Market report?

Ans: The main players in the Oncolytic Virus Cancer Immunotherapy Market are AstraZeneca, Amgen, F Hoffman-La Roche, Bristol-Myers Squibb, Novartis AG, Merck & Co., Inc., Pfizer, Biovex, Cell Genesys, Crusade Laboratories, Genelux Corporation, Lokon Pharma, MultiVir

What are the Application segmentation covered in the Oncolytic Virus Cancer Immunotherapy Market report?

Ans: The Applications covered in the Oncolytic Virus Cancer Immunotherapy Market report are Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others

What are the Type segmentation covered in the Oncolytic Virus Cancer Immunotherapy Market report?

Ans: The Types covered in the Oncolytic Virus Cancer Immunotherapy Market report are Monoclonal Antibodies, Checkpoint Inhibitors, Oncoloytic Viral Therapies and Cancer Vaccines

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Monoclonal Antibodies

1.2.3 Checkpoint Inhibitors

1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines

1.3 Market by Application

1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Lung Cancer

1.3.3 Breast Cancer

1.3.4 Colorectal Cancer

1.3.5 Melanoma

1.3.6 Prostate Cancer

1.3.7 Head and neck Cancer

1.3.8 Ovarian Cancer

1.3.9 Pancreatic Cancer

1.3.10 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2019-2030)

2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region

2.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2019-2024)

2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2025-2030)

2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics

2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends

2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers

2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges

2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue

3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2019-2024)

3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2019-2024)

3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue

3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio

3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2023

3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served

3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service

3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type

4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2019-2024)

4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2025-2030)

5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application

5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2019-2024)

5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)

6.2 North America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)

6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)

7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)

7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)

8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2019-2024)

8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)

9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)

9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)

10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)

10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AstraZeneca

11.1.1 AstraZeneca Company Detail

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction

11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.1.5 AstraZeneca Recent Development

11.2 Amgen

11.2.1 Amgen Company Detail

11.2.2 Amgen Business Overview

11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction

11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.2.5 Amgen Recent Development

11.3 F Hoffman-La Roche

11.3.1 F Hoffman-La Roche Company Detail

11.3.2 F Hoffman-La Roche Business Overview

11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction

11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.3.5 F Hoffman-La Roche Recent Development

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Detail

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction

11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.4.5 Bristol-Myers Squibb Recent Development

11.5 Novartis AG

11.5.1 Novartis AG Company Detail

11.5.2 Novartis AG Business Overview

11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction

11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.5.5 Novartis AG Recent Development

11.6 Merck & Co., Inc.

11.6.1 Merck & Co., Inc. Company Detail

11.6.2 Merck & Co., Inc. Business Overview

11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction

11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.6.5 Merck & Co., Inc. Recent Development

11.7 Pfizer

11.7.1 Pfizer Company Detail

11.7.2 Pfizer Business Overview

11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction

11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.7.5 Pfizer Recent Development

11.8 Biovex

11.8.1 Biovex Company Detail

11.8.2 Biovex Business Overview

11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction

11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.8.5 Biovex Recent Development

11.9 Cell Genesys

11.9.1 Cell Genesys Company Detail

11.9.2 Cell Genesys Business Overview

11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction

11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.9.5 Cell Genesys Recent Development

11.10 Crusade Laboratories

11.10.1 Crusade Laboratories Company Detail

11.10.2 Crusade Laboratories Business Overview

11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction

11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.10.5 Crusade Laboratories Recent Development

11.11 Genelux Corporation

11.11.1 Genelux Corporation Company Detail

11.11.2 Genelux Corporation Business Overview

11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction

11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.11.5 Genelux Corporation Recent Development

11.12 Lokon Pharma

11.12.1 Lokon Pharma Company Detail

11.12.2 Lokon Pharma Business Overview

11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction

11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.12.5 Lokon Pharma Recent Development

11.13 MultiVir

11.13.1 MultiVir Company Detail

11.13.2 MultiVir Business Overview

11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction

11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

11.13.5 MultiVir Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Monoclonal Antibodies

Table 3. Key Players of Checkpoint Inhibitors

Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines

Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2019-2024)

Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2025-2030)

Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends

Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers

Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges

Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints

Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players (2019-2024)

Table 17. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2023)

Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service

Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2019-2024)

Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2025-2030)

Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2019-2024)

Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2025-2030)

Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 47. AstraZeneca Company Detail

Table 48. AstraZeneca Business Overview

Table 49. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product

Table 50. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 51. AstraZeneca Recent Development

Table 52. Amgen Company Detail

Table 53. Amgen Business Overview

Table 54. Amgen Oncolytic Virus Cancer Immunotherapy Product

Table 55. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 56. Amgen Recent Development

Table 57. F Hoffman-La Roche Company Detail

Table 58. F Hoffman-La Roche Business Overview

Table 59. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product

Table 60. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 61. F Hoffman-La Roche Recent Development

Table 62. Bristol-Myers Squibb Company Detail

Table 63. Bristol-Myers Squibb Business Overview

Table 64. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product

Table 65. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 66. Bristol-Myers Squibb Recent Development

Table 67. Novartis AG Company Detail

Table 68. Novartis AG Business Overview

Table 69. Novartis AG Oncolytic Virus Cancer Immunotherapy Product

Table 70. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 71. Novartis AG Recent Development

Table 72. Merck & Co., Inc. Company Detail

Table 73. Merck & Co., Inc. Business Overview

Table 74. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product

Table 75. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 76. Merck & Co., Inc. Recent Development

Table 77. Pfizer Company Detail

Table 78. Pfizer Business Overview

Table 79. Pfizer Oncolytic Virus Cancer Immunotherapy Product

Table 80. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 81. Pfizer Recent Development

Table 82. Biovex Company Detail

Table 83. Biovex Business Overview

Table 84. Biovex Oncolytic Virus Cancer Immunotherapy Product

Table 85. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 86. Biovex Recent Development

Table 87. Cell Genesys Company Detail

Table 88. Cell Genesys Business Overview

Table 89. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product

Table 90. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 91. Cell Genesys Recent Development

Table 92. Crusade Laboratories Company Detail

Table 93. Crusade Laboratories Business Overview

Table 94. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product

Table 95. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 96. Crusade Laboratories Recent Development

Table 97. Genelux Corporation Company Detail

Table 98. Genelux Corporation Business Overview

Table 99. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product

Table 100. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 101. Genelux Corporation Recent Development

Table 102. Lokon Pharma Company Detail

Table 103. Lokon Pharma Business Overview

Table 104. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product

Table 105. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 106. Lokon Pharma Recent Development

Table 107. MultiVir Company Detail

Table 108. MultiVir Business Overview

Table 109. MultiVir Oncolytic Virus Cancer Immunotherapy Product

Table 110. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)

Table 111. MultiVir Recent Development

Table 112. Research Programs/Design for This Report

Table 113. Key Data Information from Secondary Sources

Table 114. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2023 VS 2030

Figure 3. Monoclonal Antibodies Features

Figure 4. Checkpoint Inhibitors Features

Figure 5. Oncoloytic Viral Therapies and Cancer Vaccines Features

Figure 6. Global Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2023 VS 2030

Figure 8. Lung Cancer Case Studies

Figure 9. Breast Cancer Case Studies

Figure 10. Colorectal Cancer Case Studies

Figure 11. Melanoma Case Studies

Figure 12. Prostate Cancer Case Studies

Figure 13. Head and neck Cancer Case Studies

Figure 14. Ovarian Cancer Case Studies

Figure 15. Pancreatic Cancer Case Studies

Figure 16. Others Case Studies

Figure 17. Oncolytic Virus Cancer Immunotherapy Report Years Considered

Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region: 2023 VS 2030

Figure 21. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2023

Figure 22. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2023)

Figure 23. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2023

Figure 24. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2019-2030)

Figure 26. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Country (2019-2030)

Figure 30. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Region (2019-2030)

Figure 38. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2019-2030)

Figure 46. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Country (2019-2030)

Figure 50. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 52. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 53. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 54. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 56. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 57. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 58. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 59. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 60. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 61. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 62. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 63. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 64. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Pediatric Cardiac Tumor Diagnostic Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-6G6046

Mon Apr 29 00:00:00 UTC 2024

Add to Cart

Global Interventional Oncology Device Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-20U7613

Mon Apr 29 00:00:00 UTC 2024

Add to Cart

Global Colon Cancer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-31C5944

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10J13802

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions